echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Allogeneic stem cell therapy! Takeda Darvadstrocel Japan applied for listing

    Allogeneic stem cell therapy! Takeda Darvadstrocel Japan applied for listing

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Takeda recently announced that it has submitted an application to Japan's Ministry of Health, Labour and Labour (MHLW) to produce and sell darvadstrocel (development code: Cx601) for the treatment of complex fistula in adult patients with in activity/mild active tube crohn's disease (CD).




    Darvadstrocel is an allogeneic (or supply source) amplified fat stem cell (eASC) suspension used to treat complex fistula in adult patients with in activityless or mildly active tube cavity CD. Darvadstrocel was awarded ODD status in the European Union, the United States and Japan in 2009, 2017 and 2019, respectively. In addition, darvadstrocel has been awarded advanced regenerative medicine (RMAT) for the treatment of complex fistula in adult PATIENTs with CD by the FDA.




    In the European Union, darvadstrocel was approved in March 2018 (trade name: Alofisel) for the treatment of complex fistula in patients with in activity/mild active tube cavity CD. Darvadstrocel is used through topical dosing to treat complex fistula in adult patients with CD who are underreacting to at least one conventional or biological therapy. Darvadstrocel should be used after fistula treatment.




    The filing includes data from two clinical trials: the Japanese study Darvadstrocel-3002 and the ADMIRE-CD trials in Europe and Israel. Darvadstrocel-3002 was a multi-center, open-label, non-control Phase 3 study conducted in 22 japanese adult in activity/mildly active tube cavity CD patients to assess the effectiveness and safety of Darvadstrocel's treatment of complex fistula. The results of the study will be presented at a recent scientific conference. ADMIRE-CD was a randomized, double-blind, controlled Phase 3 clinical trial conducted in 212 adult patients with in activity/mildly active tube cavity CD, evaluating the efficacy and safety of darvadstrocel in the treatment of complex fistula.




    Crohn's disease (CD) is a chronic inflammatory disease of the digestive system that affects about 70,000 people in Japan. CD patients may experience complex fistula, which can cause severe pain, swelling, infections, and secretions. Despite advances in medicine and surgery, complex fistulas in CDs remain a challenge for clinicians and have a negative impact on the quality of life of patients. (Bio Valley)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.